---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006384"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:49:49.009547+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aptevo appoints Lamothe COO, Taylor CFO; base salaries $470K and $404K

## Summary
- Jeffrey Lamothe promoted from EVP/CFO to EVP/COO; base salary $470,000, bonus target 45%.
- Daphne Taylor promoted from SVP Finance to SVP/CFO; base salary $403,745, bonus target 40%.
- Lamothe received 16,500 options and 16,500 RSUs vesting over 3 years under 2018 Stock Plan.
- Taylor received 11,000 options and 11,000 RSUs vesting over 3 years; effective March 3, 2023.
- No family relationships or reportable transactions involving the appointees.

## SEC filing metadata
- accession: 0000950170-23-006384
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017023006384/0000950170-23-006384-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017023006384/apvo-20230303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006384
- JSON: https://secwatch.observer/filing/0000950170-23-006384.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006384.txt

## Key facts
- Executive change
  Jeffrey G. Lamothe was appointed as Executive Vice President, Chief Operating Officer at Aptevo Therapeutics Inc..
  - Action: appointed
  - Role: Executive Vice President, Chief Operating Officer
  source text: On March 3, 2023, Aptevo Therapeutics Inc. (the “Company”) appointed Jeffrey G. Lamothe, formerly the Company’s Executive Vice President, Chief Financial Officer, to Executive Vice President, Chief Operating Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017023006384/0000950170-23-006384-index.htm
- Executive change
  Daphne Taylor was appointed as Senior Vice President, Chief Financial Officer at Aptevo Therapeutics Inc..
  - Action: appointed
  - Role: Senior Vice President, Chief Financial Officer
  source text: Also, on March 3, 2023, the Company appointed Daphne Taylor, formerly the Company’s Senior Vice President, Finance, to Senior Vice President, Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671584/000095017023006384/0000950170-23-006384-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.